Usana Health Sciences Inc (USNA) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026
Usana Health Sciences Inc (USNA)
A forensic read on Usana Health Sciences Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
5.5
Distress distance
Clean
Earnings quality
4
Forensic signals
31.2
P / E (ttm)
2.0%
ROE
$254M
Market cap
8.3%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Usana Health Sciences Inc earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 5.5, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
186d
FY2024→FY2026
Inventory days.Days inventory outstanding moved from 158 to 186 FY2024→FY2026 (against cost of goods sold; inventory +47% vs +25% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead. FY2024 and FY2026 aren't consecutive filed years here, so FY2026's opening balance can't be taken from FY2024 — both figures are measured on period-end balances rather than the beginning-plus-ending average, which keeps the two endpoints comparable to each other.
5.3%
FY2026
Return on invested capital.Return on invested capital is 5.3% in the latest fiscal year and slipping from 43% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
323% of FCF
FY2026
Shareholder returns.Returned $28M to shareholders (buybacks + dividends) in FY2026 — 323% of free cash flow. More than free cash flow generated — and beyond operating cash too, so the extra is coming from debt or cash reserves, which isn't sustainable indefinitely. Counting the $14M of stock-based comp paid out in shares on top of that, the combined claim on free cash flow is 485%.
$7M
FY2026–FY2026
Goodwill impairments.Took $7M of goodwill writedowns across 1 year (FY2026 ($7M)) — about 61% of net income over the span. A large writedown means an acquisition turned out worth far less than was paid — a real mark against M&A discipline.
Key fundamentals
Latest Revenue$925.3M
Revenue Growth YoY+8.3%
Revenue CAGR (3yr)+0.2%
Net Margin1.2%
Free Cash Flow$8.5M
Return on Equity2.0%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Usana Health Sciences Inc's actual 10-K/10-Q/8-K filings?